<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Nutrition &amp; Metabolism - Latest articles</title>
		<link>http://www.nutritionandmetabolism.com</link>
		<description>The latest articles from Nutrition &amp; Metabolism (ISSN 1743-7075) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.nutritionandmetabolism.com/content/5/1/24"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionandmetabolism.com/content/5/1/23"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionandmetabolism.com/content/5/1/22"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionandmetabolism.com/content/5/1/21"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionandmetabolism.com/content/5/1/20"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionandmetabolism.com/content/5/1/19"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionandmetabolism.com/content/5/1/18"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionandmetabolism.com/content/5/1/17"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionandmetabolism.com/content/5/1/16"/>			    
            
				    <rdf:li rdf:resource="http://www.nutritionandmetabolism.com/content/5/1/15"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.nutritionandmetabolism.com/content/5/1/24">
            
            <title>Body circumferences: clinical implications emerging from a 
new geometric model 
</title>
			<description>Background:
Body volume expands with the positive energy balance associated with the development of adult human obesity and this "growth" is captured by two widely used clinical metrics, waist circumference and body mass index (BMI). Empirical correlations between circumferences, BMI, and related body compartments are frequently reported but fail to provide an important common conceptual foundation that can be related to key clinical observations. A two-phase program was designed to fill this important gap: a geometric model linking body volume with circumferences and BMI was developed and validated in cross-sectional cohorts; and the model was applied to the evaluation of longitudinally monitored subjects during periods of voluntary weight loss. Concepts emerging from the developed model were then used to examine the relations between the evaluated clinical measures and body composition.
Methods:
Two groups of healthy adults (n=494 and 1499) were included in the cross-sectional model development/testing phase and subjects in two previous weight loss studies were included in the longitudinal model evaluation phase. Five circumferences (arm, waist, hip, thigh, and calf; average of sum, C), height (H), BMI, body volume (V; underwater weighing), and the volumes of major body compartments (whole-body magnetic resonance imaging) were measured.
Results:
The evaluation of a humanoid geometric model based a cylinder confirmed that V derived from C and H was highly correlated with measured V [R2 both males and females, 0.97; p&lt;0.001). Developed allometric models confirmed model predictions that C and BMI (represented as V/H) are directly linked as, C = (V/H)0.5. The scaling of individual circumferences to V/H varied, with waist the highest (V/H~0.6) and calf the lowest (V/H~0.3), indicating that the largest and smallest between-subject "growth" with greater body volume occurs in the abdominal area and lower extremities, respectively. A stepwise linear regression model including all five circumferences2 showed that each contributed independently to V/H. These cross-sectional observations were generally confirmed by analysis of the two longitudinal weight loss studies. The scaling of circumference ratios (e.g., waist/hip) to V/H conformed to models developed on the scaling of individual circumferences to V/H, indicating their relations to BMI are predictable a priori. Waist, hip, and arm/calf circumferences had the highest associations with whole-body visceral adipose tissue, subcutaneous adipose tissue, and skeletal muscle volumes, respectively.
Conclusions:
These observations provide a simple geometric model relating circumferences with body size and composition, introduce a conceptual foundation explaining previous empirical observations, and reveal new clinical insights.</description>
			<link>http://www.nutritionandmetabolism.com/content/5/1/24</link>
			
			 	<dc:creator>Steven B Heymsfield, Allison Martin-Nguyen, Tung M Fong, Dympna Gallagher and Angelo Pietrobelli</dc:creator>
			
			<dc:source>Nutrition &amp; Metabolism 2008, 5:24</dc:source>
			<dc:date>2008-10-06</dc:date>
			<dc:identifier>doi:10.1186/1743-7075-5-24</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition &amp; Metabolism</prism:publicationName>
					
			
							
					<prism:issn>1743-7075</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>24</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-10-06</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionandmetabolism.com/content/5/1/23">
            
            <title>A high throughput live transparent animal bioassay to identify non-toxic small molecules or genes that regulate vertebrate fat metabolism for obesity drug development</title>
			<description>Background:
The alarming rise in the obesity epidemic and growing concern for the pathologic consequences of the metabolic syndrome warrant great need for development of obesity-related pharmacotherapeutics. The search for such therapeutics is severely limited by the slow throughput of animal models of obesity. Amenable to placement into a 96 well plate, zebrafish larvae have emerged as one of the highest throughput vertebrate model organisms for performing small molecule screens. A method for visually identifying non-toxic molecular effectors of fat metabolism using a live transparent vertebrate was developed. Given that increased levels of nicotinamide adenine dinucleotide (NAD) via deletion of CD38 have been shown to prevent high fat diet induced obesity in mice in a SIRT-1 dependent fashion we explored the possibility of directly applying NAD to zebrafish.
Methods:
Zebrafish larvae were incubated with daily refreshing of nile red containing media starting from a developmental stage of equivalent fat content among siblings (3 days post-fertilization, dpf) and continuing with daily refreshing until 7 dpf.
Results:
PPAR activators, beta-adrenergic agonists, SIRT-1 activators, and nicotinic acid treatment all caused predicted changes in fat, cholesterol, and gene expression consistent with a high degree of evolutionary conservation of fat metabolism signal transduction extending from man to zebrafish larvae. All changes in fat content were visually quantifiable in a relative fashion using live zebrafish larvae nile red fluorescence microscopy. Resveratrol treatment caused the greatest and most consistent loss of fat content. The resveratrol tetramer Vaticanol B caused loss of fat equivalent in potency to resveratrol alone. Significantly, the direct administration of NAD decreased fat content in zebrafish. Results from knockdown of a zebrafish G-PCR ortholog previously determined to decrease fat content in C. elegans support that future GPR142 antagonists may be effective non-toxic anti-obesity therapeutics.
Conclusion:
Owing to the apparently high level of evolutionary conservation of signal transduction pathways regulating lipid metabolism, the zebrafish can be useful for identifying non-toxic small molecules or pharmacological target gene products for developing molecular therapeutics for treating clinical obesity. Our results support the promising potential in applying NAD or resveratrol where the underlying target protein likely involves Sirtuin family member proteins. Furthermore data supports future studies focused on determining whether there is a high concentration window for resveratrol that is effective and non-toxic in high fat obesity murine models.</description>
			<link>http://www.nutritionandmetabolism.com/content/5/1/23</link>
			
			 	<dc:creator>Kevin S Jones, Alexander P Alimov, Horacio L Rilo, Ronald J Jandacek, Laura A Woollett and W Todd Penberthy</dc:creator>
			
			<dc:source>Nutrition &amp; Metabolism 2008, 5:23</dc:source>
			<dc:date>2008-08-27</dc:date>
			<dc:identifier>doi:10.1186/1743-7075-5-23</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition &amp; Metabolism</prism:publicationName>
					
			
							
					<prism:issn>1743-7075</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>23</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionandmetabolism.com/content/5/1/22">
            
            <title>Conjugated linoleic acid modulation of risk factors associated with atherosclerosis</title>
			<description>Conjugated linoleic acid (CLA) has been the subject of extensive investigation regarding its possible benefits on a variety of human diseases. In some animal studies, CLA has been shown to have a beneficial effect on sclerotic lesions associated with atherosclerosis, be a possible anti-carcinogen, increase feed efficiency, and act as a lean body mass supplement. However, the results have been inconsistent, and the effects of CLA on atherogenesis appear to be dose-, isomer-, tissue-, and species-specific. Similarly, CLA trials in humans have resulted in conflicting findings. Both the human and animal study results may be attributed to contrasting doses of CLA, isomers, the coexistence of other dietary fatty acids, length of study, and inter-and/or intra-species diversities. Recent research advances have suggested the importance of CLA isomers in modulating gene expression involved in oxidative damage, fatty acid metabolism, immune/inflammatory responses, and ultimately atherosclerosis. Although the possible mechanisms of action of CLA have been suggested, they have yet to be determined.</description>
			<link>http://www.nutritionandmetabolism.com/content/5/1/22</link>
			
			 	<dc:creator>Yukiko K Nakamura, Nichole Flintoff-Dye and Stanley T Omaye</dc:creator>
			
			<dc:source>Nutrition &amp; Metabolism 2008, 5:22</dc:source>
			<dc:date>2008-08-21</dc:date>
			<dc:identifier>doi:10.1186/1743-7075-5-22</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition &amp; Metabolism</prism:publicationName>
					
			
							
					<prism:issn>1743-7075</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>22</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-21</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionandmetabolism.com/content/5/1/21">
            
            <title>Skeletal muscle munc18c and syntaxin 4 in human obesity</title>
			<description>Background:
Animal and cell culture data suggest a critical role for Munc18c and Syntaxin 4 proteins in insulin mediated glucose transport in skeletal muscle, but no studies have been published in humans.
Methods:
We investigated the effect of a 12 vs. 48 hr fast on insulin action and skeletal muscle Munc18c and Syntaxin 4 protein in lean and obese subjects. Healthy lean (n = 14; age = 28.0 +/- 1.4 yr; BMI = 22.8 +/- 0.42 kg/m2) and obese subjects (n = 11; age = 34.6 +/- 2.3 yr; BMI = 36.1 +/- 1.5 kg/m2) were studied twice following a 12 and 48 hr fast. Skeletal muscle biopsies were obtained before a 3 hr 40 mU/m2/min hyperinsulinemic-euglycemic clamp with [6,6-2H2]glucose infusion.
Results:
Glucose rate of disappearance (Rd) during the clamp was lower in obese vs. lean subjects after the 12 hr fast (obese: 6.25 +/- 0.67 vs. lean: 9.42 +/- 1.1 mg/kgFFM/min, p = 0.007), and decreased significantly in both groups after the 48 hr fast (obese 3.49 +/- 0.31 vs. lean: 3.91 +/- 0.42 mg/kgFFM/min, p = 0.002). Munc18c content was not significantly different between lean and obese subjects after the 12 hour fast, and decreased after the 48 hr fast in both groups (p = 0.013). Syntaxin 4 content was not altered by obesity or fasting duration. There was a strong positive relationship between plasma glucose concentration and Munc18c content in lean and obese subjects during both 12 and 48 hr fasts (R2 = 0.447, p = 0.0015). Significant negative relationships were also found between Munc18c and FFA (p = 0.041), beta-hydroxybutyrate (p = 0.039), and skeletal muscle AKT content (p = 0.035) in lean and obese subjects.
Conclusion:
These data indicate Munc18c and Syntaxin 4 are present in human skeletal muscle. Munc18c content was not significantly different between lean and obese subjects, and is therefore unlikely to explain obesity-induced insulin resistance. Munc18c content decreased after prolonged fasting in lean and obese subjects concurrently with reduced insulin action. These data suggest changes in Munc18c content in skeletal muscle are associated with short-term changes in insulin action in humans.</description>
			<link>http://www.nutritionandmetabolism.com/content/5/1/21</link>
			
			 	<dc:creator>Bryan C Bergman, Marc-Andre Cornier, Tracy J Horton, Daniel H Bessesen and Robert H Eckel</dc:creator>
			
			<dc:source>Nutrition &amp; Metabolism 2008, 5:21</dc:source>
			<dc:date>2008-07-24</dc:date>
			<dc:identifier>doi:10.1186/1743-7075-5-21</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition &amp; Metabolism</prism:publicationName>
					
			
							
					<prism:issn>1743-7075</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>21</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-24</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionandmetabolism.com/content/5/1/20">
            
            <title>Potential antiproteolytic effects of L-leucine: observations of in vitro and in vivo studies</title>
			<description>The purpose of present review is to describe the effect of leucine supplementation on skeletal muscle proteolysis suppression in both in vivo and in vitro studies. Most studies, using in vitro methodology, incubated skeletal muscles with leucine with different doses and the results suggests that there is a dose-dependent effect. The same responses can be observed in in vivo studies. Importantly, the leucine effects on skeletal muscle protein synthesis are not always connected to the inhibition of skeletal muscle proteolysis. As a matter of fact, high doses of leucine incubation can promote suppression of muscle proteolysis without additional effects on protein synthesis, and low leucine doses improve skeletal muscle protein ynthesis but have no effect on skeletal muscle proteolysis. These research findings may have an important clinical relevancy, because muscle loss in atrophic states would be reversed by specific leucine supplementation doses. Additionally, it has been clearly demonstrated that leucine administration suppresses skeletal muscle proteolysis in various catabolic states. Thus, if protein metabolism changes during different atrophic conditions, it is not surprising that the leucine dose-effect relationship must also change, according to atrophy or pathological state and catabolism magnitude. In conclusion, leucine has a potential role on attenuate skeletal muscle proteolysis. Future studies will help to sharpen the leucine efficacy on skeletal muscle protein degradation during several atrophic states.</description>
			<link>http://www.nutritionandmetabolism.com/content/5/1/20</link>
			
			 	<dc:creator>Nelo E Zanchi, Humberto Nicastro and Antonio H Lancha</dc:creator>
			
			<dc:source>Nutrition &amp; Metabolism 2008, 5:20</dc:source>
			<dc:date>2008-07-17</dc:date>
			<dc:identifier>doi:10.1186/1743-7075-5-20</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition &amp; Metabolism</prism:publicationName>
					
			
							
					<prism:issn>1743-7075</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>20</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-17</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionandmetabolism.com/content/5/1/19">
            
            <title>Unsaturated long-chain fatty acids induce the respiratory burst of human neutrophils and monocytes in whole blood</title>
			<description>Background:
It is increasingly recognized that infectious complications in patients treated with total parenteral nutrition (TPN) may be caused by altered immune responses. Neutrophils and monocytes are the first line of defence against bacterial and fungal infection through superoxide anion production during the respiratory burst. To characterize the impact of three different types of lipid solutions that are applied as part of TPN formulations, we investigated the unstimulated respiratory burst activation of neutrophils and monocytes in whole blood.
Methods:
Whole blood samples were incubated with LCT (Intralipid&#174;), LCT/MCT (Lipofundin&#174;) and LCT-MUFA (ClinOleic&#174;) in three concentrations (0.06, 0.3 and 0.6 mg ml-1) for time periods up to one hour. Hydrogen peroxide production during the respiratory burst of neutrophils and monocytes was measured by flow cytometry.
Results:
LCT and LCT-MUFA induced a hydrogen peroxide production in neutrophils and monocytes without presence of a physiological stimulus in contrast to LCT/MCT.
Conclusion:
We concluded that parenteral nutrition containing unsaturated oleic (C18:1) and linoleic (C18:2) acid can induce respiratory burst of neutrophils and monocytes, resulting in an elevated risk of tissue damage by the uncontrolled production of reactive oxygen species. Contradictory observations reported in previous studies may in part be the result of different methods used to determine hydrogen peroxide production.</description>
			<link>http://www.nutritionandmetabolism.com/content/5/1/19</link>
			
			 	<dc:creator>Bj&#246;rn J&#252;ttner, Janina Kr&#246;plin, Sina M Coldewey, Lars Witt, Wilhelm A Osthaus, Christian Weilbach and Dirk Scheinichen</dc:creator>
			
			<dc:source>Nutrition &amp; Metabolism 2008, 5:19</dc:source>
			<dc:date>2008-07-14</dc:date>
			<dc:identifier>doi:10.1186/1743-7075-5-19</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition &amp; Metabolism</prism:publicationName>
					
			
							
					<prism:issn>1743-7075</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>19</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-14</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionandmetabolism.com/content/5/1/18">
            
            <title>Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals</title>
			<description>Background:
The first line anti-tuberculosis drugs isoniazid (INH), rifampicin (RIF) and pyrazinamide (PZA) continues to be the effective drugs in the treatment of tuberculosis, however, the use of these drugs is associated with toxic reactions in tissues, particularly in the liver, leading to hepatitis. Silymarin, a standard plant extract with strong antioxidant activity obtained from S. marianum, is known to be an effective agent for liver protection and liver regeneration. The aim of this study was to investigate the protective actions of silymarin against hepatotoxicity caused by different combinations of anti-tuberculosis drugs.
Methods:
Male Wistar albino rats weighing 250&#8211;300 g were used to form 6 study groups, each group consisting of 10 rats. Animals were treated with intra-peritoneal injection of isoniazid (50 mg/kg) and rifampicin (100 mg/kg); and intra-gastric administration of pyrazinamid (350 mg/kg) and silymarin (200 mg/kg). Hepatotoxicity was induced by a combination of drugs with INH+RIF and INH+RIF+PZA. Hepatoprotective effect of silymarin was investigated by co-administration of silymarin together with the drugs. Serum biochemical tests for liver functions and histopathological examination of livers were carried out to demonstrate the protection of liver against anti-tuberculosis drugs by silymarin.
Results:
Treatment of rats with INH+RIF or INH+RIF+PZA induced hepatotoxicity as evidenced by biochemical measurements: serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) activities and the levels of total bilirubin were elevated, and the levels of albumin and total protein were decreased in drugs-treated animals. Histopathological changes were also observed in livers of animals that received drugs. Simultaneous administration of silymarin significantly decreased the biochemical and histological changes induced by the drugs.
Conclusion:
The active components of silymarin had protective effects against hepatotoxic actions of drugs used in the chemotherapy of tuberculosis in animal models. Since no significant toxicity of silymarin is reported in human studies, this plant extract can be used as a dietary supplement by patients taking anti-tuberculosis medications.</description>
			<link>http://www.nutritionandmetabolism.com/content/5/1/18</link>
			
			 	<dc:creator>Sude Eminzade, Fikriye Uraz and Fikret V Izzettin</dc:creator>
			
			<dc:source>Nutrition &amp; Metabolism 2008, 5:18</dc:source>
			<dc:date>2008-07-05</dc:date>
			<dc:identifier>doi:10.1186/1743-7075-5-18</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition &amp; Metabolism</prism:publicationName>
					
			
							
					<prism:issn>1743-7075</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>18</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-05</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionandmetabolism.com/content/5/1/17">
            
            <title>Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes</title>
			<description>Background:
Adipocytes express inflammatory mediators that contribute to the low-level, chronic inflammation found in obese subjects and have been linked to the onset of cardiovascular disorders and insulin resistance associated with type 2 diabetes mellitus. A reduction in inflammatory gene expression in adipocytes would be expected to reverse this low-level, inflammatory state and improve cardiovascular function and insulin sensitivity. The natural products, curcumin and resveratrol, are established anti-inflammatory compounds that mediate their effects by inhibiting activation of NF-&#954;B signaling. In the present study, we examined if these natural products can inhibit NF-&#954;B activation in adipocytes and in doing so reduce cytokine expression.
Methods:
Cytokine (TNF-&#945;, IL-1&#946;, IL-6) and COX-2 gene expression in 3T3-L1-derived adipocytes was measured by quantitative real-time PCR (qRT-PCR) with or without TNF&#945;-stimulation. Cytokine protein and prostaglandin E2 (PGE2) expression were measured by ELISA. Effects of curcumin and resveratrol were evaluated by treating TNF&#945;-stimulated adipocytes with each compound and 1) assessing the activation state of the NF-&#954;B signaling pathway and 2) measuring inflammatory gene expression by qRT-PCR and ELISA.
Results:
Both preadipocytes and differentiated adipocytes express the genes for TNF-&#945;, IL-6, and COX-2, key mediators of the inflammatory response. Preadipocytes were also found to express IL-1&#946;; however, IL-1&#946; expression was absent in differentiated adipocytes. TNF-&#945; treatment activated NF-&#954;B signaling in differentiated adipocytes by inducing I&#954;B degradation and NF-&#954;B translocation to the nucleus, and as a result increased IL-6 (6-fold) and COX-2 (2.5-fold) mRNA levels. TNF-&#945; also activated IL-1&#946; gene expression in differentiated adipocytes, but had no effect on endogenous TNF-&#945; mRNA levels. No detectable TNF&#945; or IL-1&#946; was secreted by adipocytes. Curcumin and resveratrol treatment inhibited NF-&#954;B activation and resulted in a reduction of TNF-&#945;, IL-1&#946;, IL-6, and COX-2 gene expression (IC50 = 2 &#956;M) and a reduction of secreted IL-6 and PGE2 (IC50 ~ 20 &#956;M).
Conclusion:
Curcumin and resveratrol are able to inhibit TNF&#945;-activated NF-&#954;B signaling in adipocytes and as a result significantly reduce cytokine expression. These data suggest that curcumin and resveratrol may provide a novel and safe approach to reduce or inhibit the chronic inflammatory properties of adipose tissue.</description>
			<link>http://www.nutritionandmetabolism.com/content/5/1/17</link>
			
			 	<dc:creator>Amanda M Gonzales and Robert A Orlando</dc:creator>
			
			<dc:source>Nutrition &amp; Metabolism 2008, 5:17</dc:source>
			<dc:date>2008-06-12</dc:date>
			<dc:identifier>doi:10.1186/1743-7075-5-17</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition &amp; Metabolism</prism:publicationName>
					
			
							
					<prism:issn>1743-7075</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>17</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionandmetabolism.com/content/5/1/16">
            
            <title>Physico-chemical modifications of conjugated linoleic acid for ruminal protection and oxidative stability</title>
			<description>Conjugated linoleic acid (CLA) is a mixture of positional and geometric isomers of octadecadienoic acid [linoleic acid (LA), 18:2n-6]. Although ruminant milk and meat products represent the largest natural source of CLA and therefore, their concentration in ruminant lipids are of interest to human health, chemical or physical modifications of CLA should be needed as a means to enhance oxidative stability, to improve post-ruminal bioavailability, and to increase the clinical application. In fact, CLA are rapidly decomposed to form furan fatty acids when its are oxidized in air, and the effectiveness of dietary supplements of CLA may be related to the extent that their metabolisms by rumen bacteria are avoided. For these reasons, many scientists have examined the effect of manufacturing and protection on the stability of CLA in ruminants and food products. In this review, physico-chemical modifications of CLA for ruminal protection such as calcium salt (Ca), formaldehyde protection (FP), lipid encapsulation (LE), and amide linkage (AL), and for oxidative stability such as green tea catechin (GTC), cyclodextrin (CD), arginine (Arg), amylase, and PEGylation are proposed.</description>
			<link>http://www.nutritionandmetabolism.com/content/5/1/16</link>
			
			 	<dc:creator>Hyun-Seuk Moon, Hong-Gu Lee, Chung-Soo Chung, Yun-Jaie Choi and Chong-Su Cho</dc:creator>
			
			<dc:source>Nutrition &amp; Metabolism 2008, 5:16</dc:source>
			<dc:date>2008-06-01</dc:date>
			<dc:identifier>doi:10.1186/1743-7075-5-16</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition &amp; Metabolism</prism:publicationName>
					
			
							
					<prism:issn>1743-7075</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>16</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-01</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.nutritionandmetabolism.com/content/5/1/15">
            
            <title>S100B concentration in colostrums of Burkinabe and Sicilian women</title>
			<description>The aim of this study is to determine the S100B concentration in colostrums of 51 Burkinabe and 30 Sicilian women, still living in their countries, and in case of a difference to search for its explanations, considering also ethnic differences.The concentration of S100B, in colostrums of the first three days from the delivery, was assessed with commercial immunoluminometric assay.The production of colostrums was significantly higher in Burkinabe women, where the colostrums S100B levels in the first day of lactation showed to be at 24 h higher than those of Sicilian mothers (672.21 &#177; 256.67 ng/ml vs 309.36 &#177; 65.28 ng/ml) and progressively decreased reaching the values of Sicilian mothers in the second and third day (204.31 &#177; 63.25 ng/ml and 199.42 &#177; 45.28 ng/ml, respectively). Correlation was found between the level of S100B and the length of stage II (duration of expulsive phase of delivery), but the correlation with pain was found only in Burkinabe women.The S100B level in colostrums of Burkinabe mothers differs from that of Sicilians only in the first day of lactation, and in consideration that Burkinabe women produce more colostrums, their newborns receive, during the first days of life, an higher amount of S100B. The elevated quantity of S100B ingested by Burkinabe newborn in the first days of life could promote the physiological postnatal brain adaptation and maturation in the precarious delivery condition of African infants.</description>
			<link>http://www.nutritionandmetabolism.com/content/5/1/15</link>
			
			 	<dc:creator>Maria Musumeci, Pasqua Betta, Emanuela Magro, Teresa Isaia, Jacques Simpore, Domenico MM Romeo and Salvatore Musumeci</dc:creator>
			
			<dc:source>Nutrition &amp; Metabolism 2008, 5:15</dc:source>
			<dc:date>2008-05-22</dc:date>
			<dc:identifier>doi:10.1186/1743-7075-5-15</dc:identifier>
			
			
							
					<prism:publicationName>Nutrition &amp; Metabolism</prism:publicationName>
					
			
							
					<prism:issn>1743-7075</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>15</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
